Thomas Hasselager

482 citations
15 papers · 359 indexed · h-index 11
Topics
Cancer Immunotherapy and Biomarkers (6 papers)CAR-T cell therapy research (5 papers)Immunotherapy and Immune Responses (3 papers)
Partner nations
DenmarkGermanyAustria

In The Last Decade

Thomas Hasselager

15 papers receiving 353 citations

Peers

Thomas Hasselager
Comparison fields: 5 of 57
  • Oncology 218
  • Immunology 151
  • Biophysics 56
  • Molecular Biology 51
  • Biomedical Engineering 50
Replace Lu Qi with:
Lu Qi China
Harald Voth Germany
Joshua Leinwand United States
Diana Shinko Australia
Haiting Ma United States
Gage Brummer United States
Taylor A. Johnson United States
Hege F. Berg Norway
Corina Behrenbruch Australia
Thomas Hasselager relative to Lu Qi China Lu Qi's profile →
Citations per field
00.5×10×15×18.7×
Lu Qi · 1×
Citations per year

Countries citing papers authored by Thomas Hasselager

Since Specialization
Citations

This map shows the geographic impact of Thomas Hasselager's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Hasselager with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Hasselager more than expected).

Fields of papers citing papers by Thomas Hasselager

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Hasselager. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Hasselager. The network helps show where Thomas Hasselager may publish in the future.

Co-authorship network of co-authors of Thomas Hasselager

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Hasselager. A scholar is included among the top collaborators of Thomas Hasselager based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Hasselager. Thomas Hasselager is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
#WorkIndexed citations
1 1
2 2
3 32
4 12
5 26
6 25
7 48
8 31
9 57
10 10
11 89
12 1
13 4
14 10
15 11

About Thomas Hasselager

Thomas Hasselager is a scholar working on Biophysics, Analytical Chemistry and Oncology, having authored 15 papers that have together received 359 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (6 papers), CAR-T cell therapy research (5 papers) and Immunotherapy and Immune Responses (3 papers). The work is most often cited by research in Biophysics (56 citations), Oncology (218 citations) and Immunology (151 citations). Thomas Hasselager has collaborated with scholars based in Denmark, Germany and Austria. Frequent co-authors include Marco Donia, Marie Christine Wulff Westergaard, Inge Marie Svane, Magnus Pedersen, Rikke Andersen, Julie Westerlin Kjeldsen, Brad H. Nelson, Katy Milne, Stacey Ledoux and Troels Holz Borch. Their work appears in journals such as Scientific Reports, British Journal of Cancer and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026